证券代码： 301097 证券简称：天益医疗 公告编号：2023-038 宁波天益医疗器械股份有限公司 关于首发前限售股东减持计划期限届满的公告 股东上海金浦国调并购股权投资基金合伙企业（有限合伙）保证向本公司提 供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 宁波天益医疗器械股份有限公司（以下简称"天益医疗"、"公司"）于 2023 年 4 月 14 日在巨潮资讯网披露了《关于首发前限售股东减持计划的预披露 公告》（公告编号：2023-008），公司首发前限售股东上海金浦国调并购股权投 资基金合伙企业（有限合伙）（以下简称"金浦国调基金"）计划在公告披露之 日起 15 个交易日后的 3 个月内，以集中竞价及大宗交易方式减持公司股份不超 过 1,178,946 股（不超过公司股份总数的 2%），其中通过集中竞价方式减持的股 份总数不超过 589,473 股（不超过公司股份总数的 1%），通过大宗交易方式减 持的股份总数不超过 589,473 股（不超过公司股份总数的 1%）。 截至本公告披露之日，金浦国调基金之减持计划时间 ...

证券代码：301097 证券简称：天益医疗 宁波天益医疗器械股份有限公司 投资者关系活动记录表 编号：2023-001 | 投资者关系活动类别 | ☐特定对象调研 ☐分析师会议 | | --- | --- | | | ☐媒体采访 业绩说明会 | | | ☐新闻发布会 ☐路演活动 | | | ☐现场参观 | | | ☐其他（请文字说明其他活动内容） | | 形式 | ☐现场 网上 ☐电话会议 | | 参与单位名称及人员姓名 | 线上参与公司2022年度网上业绩说明会的投资者 | | 时间 | 2023年05月23日 15:00-17:00 | | 地点 | 价值在线（https://www.ir-online.cn/） | | 上市公司接待人员姓名 | 董事长、总经理 吴志敏 董事、副总经理、财务总监 张重良 | | | 副总经理、董事会秘书 李孟良 | | | 独立董事 奚盈盈 1.公司去年的分红方案是每10股派2.5元，今年在营收没 | | | 有明显增长的情况下，分红规模却超去年，是基于什么考 | | 投资者关系活动主要内容 | 量？ | | 介绍 | 回复:公司制定的利润分配预案是在保证公司正常经营 ...

证券代码： 301097 证券简称：天益医疗 公告编号：2023-025 宁波天益医疗器械股份有限公司 关于举办 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 宁波天益医疗器械股份有限公司（以下简称"公司"）已于 2023 年 04 月 21 日在巨潮资讯网上披露了《宁波天益医疗器械股份有限公司 2022 年年度报 告全文》及《宁波天益医疗器械股份有限公司 2022 年年度报告摘要》。为便于 广大投资者更加全面深入地了解公司经营业绩、发展战略等情况，公司定于 2023 年 05 月 23 日（星期二）15:00-17:00 在"价值在线"（www.ir-online.cn ）举办宁波天益医疗器械股份有限公司 2022 年度网上业绩说明会，与投资者进 行沟通和交流，广泛听取投资者的意见和建议。 1 会议召开时间：2023 年 05 月 23 日（星期二）15:00-17:00 会议召开方式：网络互动方式 会议召开地点：价值在线（www.ir-online.cn） 会 议 问 题 征 集 ： 投 资 者 可 于 ...

宁波天益医疗器械股份有限公司 2023 年第一季度报告 证券代码：301097 证券简称：天益医疗 公告编号：2023-022 宁波天益医疗器械股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经过审计 □是 否 1 宁波天益医疗器械股份有限公司 2023 年第一季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 是 □否 追溯调整或重述原因 □会计政策变更 □会计差错更正 同一控制下企业合并 □其他原因 | | 本报告期 | 上年同期 | | 本报告期比上年同期 | | --- | --- | --- | --- | --- | | | | | | 增减（%） | | | | 调 ...

Financial Performance - The company’s operating revenue for 2022 was ¥399,325,371.39, a decrease of 3.71% compared to ¥414,731,858.47 in 2021[22]. - Net profit attributable to shareholders increased by 9.34% to ¥85,604,071.60 in 2022 from ¥78,292,042.29 in 2021[22]. - The net profit after deducting non-recurring gains and losses was ¥65,771,738.94, down 9.99% from ¥73,074,983.57 in the previous year[22]. - The net cash flow from operating activities decreased significantly by 62.28% to ¥50,177,065.73 from ¥133,029,877.97 in 2021[22]. - Basic earnings per share were ¥1.55, a decline of 12.43% from ¥1.77 in 2021[22]. - Total assets at the end of 2022 reached ¥1,627,081,762.90, an increase of 101.55% from ¥807,284,424.94 at the end of 2021[22]. - Net assets attributable to shareholders rose by 163.05% to ¥1,234,868,730.71 from ¥469,438,292.18 in 2021[22]. - The company reported a quarterly revenue of ¥120,493,264.29 in Q4 2022, showing a steady increase throughout the year[24]. - The company experienced a net loss of ¥1,407,761.26 in Q4 2022, contrasting with profits in the earlier quarters[24]. - The weighted average return on equity decreased to 8.36% in 2022 from 18.20% in 2021, indicating a decline in profitability[22]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 5.00 RMB per 10 shares to all shareholders, based on a total of 58,947,368 shares[3]. - The total distributable profit for the year was RMB 382,393,454.39, with the cash dividend amounting to 100% of the profit distribution[183]. - The company reported a cash dividend of RMB 5.00 per 10 shares, totaling RMB 29,473,684.00, which represents 100% of the total profit distribution[183]. - The company has a total of 58,947,368 shares, with no stock bonus or capital reserve conversion planned for this year[185]. Risk Management - The report emphasizes the importance of risk awareness regarding forward-looking statements and future plans[3]. - The company has a comprehensive risk management strategy outlined in the management discussion section, detailing potential operational risks and mitigation measures[3]. - The company is actively managing financial risks, including currency fluctuations, as a significant portion of its revenue comes from foreign sales settled in USD, which exposes it to exchange rate volatility[133]. - The company acknowledges potential risks from fluctuating gross margins, particularly in its main product lines, which could adversely affect profitability if production costs cannot be managed effectively[129]. - The company faces risks related to customer concentration, particularly with significant reliance on Avanos Medical for sales of feeding devices and tubes, which could impact order sustainability if this client reduces demand[130]. Research and Development - The company has a dedicated R&D team of 120 members, accounting for 10.70% of total employees, focusing on product development and technological innovation[69]. - The company invested a total of 28.06 million yuan in R&D during the reporting period, with R&D expenses accounting for 7.03% of operating revenue, representing a year-on-year increase of 38.50%[70]. - The company is focusing on developing domestic alternatives for imported blood purification products, which is expected to enhance competitiveness and reduce healthcare costs[95]. - R&D investment increased from ¥20,261,432.48 in 2021 to ¥28,061,366.99 in 2022, a year-on-year increase of 38.50%[96]. - The company has developed new products such as disposable integrated oxygen tubes and blood dialysis concentrates, achieving significant economic benefits while focusing on high-value products in the blood purification field[71]. Market Presence and Sales - The company has a significant market presence, covering over 1,000 hospitals and 450 top-tier hospitals across 31 provinces and municipalities in China[66]. - The company ranks second in the market share for extracorporeal circulation blood lines in China, indicating strong competitiveness in the industry[67]. - The company’s products are sold across all 31 provinces and regions in China and exported to Asia, Europe, North America, South America, and Africa[45]. - Domestic sales reached CNY 233.98 million, up 12.46% year-on-year, while overseas sales dropped by 20.00% to CNY 165.35 million[84]. - The blood purification segment generated revenue of CNY 220.37 million, accounting for 55.18% of total revenue, reflecting a decline of 16.10% year-on-year[83]. Corporate Governance - The board of directors consists of 7 members, including 3 independent directors, complying with legal and regulatory requirements[138]. - The supervisory board is composed of 3 members, including 1 employee representative, ensuring compliance with legal standards[139]. - The company maintains independence in assets, personnel, finance, organization, and business from its controlling shareholders and actual controllers[144][145][146][147][148]. - The company has established a comprehensive internal control system, including rules for shareholder meetings and specialized committees to ensure effective governance[186]. - The company emphasizes transparency and timely information disclosure, adhering to relevant laws and regulations[141]. Quality Control and Compliance - The company has established a comprehensive quality control system, ensuring that no quality-related medical accidents or disputes occurred during the reporting period[75]. - The company has passed EN ISO 13485:2016 quality management system certification and has received EU MDR certification in January 2023, indicating compliance with international quality standards[75]. - The company emphasizes product quality by adhering to various medical device regulations and continuously improving its quality control system[197]. - The company has established a robust internal control system to ensure compliance with relevant laws and regulations[195]. - The company has no environmental penalties reported during the reporting period, indicating compliance with environmental regulations[194]. Social Responsibility and Employee Welfare - The company is committed to social responsibility and aims to contribute positively to community welfare while ensuring employee satisfaction[128]. - The company promotes a work-life balance and fosters a positive work environment through various employee care activities[200]. - The company aims to create a harmonious work environment while promoting employee development through targeted training programs[180]. - The company emphasizes the importance of customer needs and employee well-being while actively fulfilling social responsibilities[125]. - The company adheres to labor laws and regulations, ensuring fair treatment of employees and prohibiting child labor and forced labor[199].

Financial Performance - The company's revenue for Q3 2022 was CNY 106,166,400.56, a decrease of 10.82% compared to the same period last year[5]. - Net profit attributable to shareholders for Q3 2022 was CNY 43,195,485.31, an increase of 45.60% year-on-year[5]. - The basic earnings per share for Q3 2022 was CNY 0.80, reflecting a growth of 19.13% compared to the previous year[5]. - Total revenue for the third quarter was CNY 278,832,107.10, a decrease of 6.4% compared to CNY 297,263,653.44 in the same period last year[29]. - The net profit for the third quarter of 2022 was CNY 87,104,476.44, an increase of 54.6% compared to CNY 56,394,447.39 in the same period last year[30]. - The total comprehensive income attributable to the parent company was CNY 87,264,292.63, compared to CNY 56,394,447.39 in the same quarter last year[30]. - The company reported a net profit margin improvement, with net profit increasing significantly due to reduced costs and increased operating efficiency[29]. Assets and Equity - Total assets at the end of Q3 2022 reached CNY 1,588,300,645.89, representing a significant increase of 96.75% year-on-year[5]. - Shareholders' equity attributable to the parent company increased by 163.41% year-on-year, amounting to CNY 1,236,528,951.74[5]. - Total assets increased significantly to CNY 1,588,300,645.89 from CNY 807,284,424.94, marking an increase of 96.5%[27]. - The company's equity attributable to shareholders increased to CNY 1,236,528,951.74 from CNY 469,438,292.18, a substantial increase of 163.5%[27]. Cash Flow - Cash flow from operating activities decreased by 61.06% year-to-date, primarily due to declining cash inflows from revenue and increased cash outflows for expenses[10]. - The cash flow from operating activities showed a net inflow of CNY 38,936,019.62, down 61.0% from CNY 99,994,387.20 in the prior year[31]. - The cash and cash equivalents at the end of the period amounted to CNY 470,407,387.02, up 89.5% from CNY 248,156,307.34 at the end of the previous year[32]. - The company experienced a cash inflow of CNY 1,085,475,371.56 from financing activities, a substantial increase from CNY 203,500,000.00 in the previous year[32]. Investment and Development - The company plans to invest approximately RMB 500 million in the Ningxiang High-tech Industrial Park to establish a manufacturing base for blood dialysis consumables and ICU continuous blood purification equipment[18]. - The company is actively engaged in planning and project bidding for the Ningxiang manufacturing base, in compliance with relevant regulations[18]. - The company is currently in the registration review stage for a Class III blood purification pipeline, which is an upgrade of an existing product[23]. - The company has a total of 5 new products under development, including a Class II gastrointestinal nutrition infusion pipeline and a Class II nasal feeding tube[23]. - The company is focused on improving patient outcomes through the development of specialized medical devices[23]. - Future outlook includes continued investment in new product development and market expansion strategies to drive growth[29]. Regulatory and Market Presence - The company has established a subsidiary in Singapore and plans to set up a subsidiary in Hong Kong, enhancing its international market presence and competitiveness[19]. - The company received a Class III medical device registration certificate for the disposable blood dialysis tubing on September 19, 2022, valid for five years until September 18, 2027[20]. - The company reported a total of 28 registered medical devices, with various classifications including Class II and Class III[21]. - The company has received multiple approvals for its medical devices, ensuring compliance with regulatory standards[21]. - The company aims to enhance its market presence through strategic product development and regulatory approvals[22]. - The company is committed to continuous innovation in medical technology to meet evolving healthcare needs[23]. Operating Costs and Efficiency - Total operating costs decreased to CNY 209,151,373.23 from CNY 235,654,235.86, reflecting a reduction of 11.2%[29]. - Operating profit increased to CNY 100,959,416.63, up from CNY 64,912,235.60, representing a growth of 55.5%[29]. - Research and development expenses were CNY 18,817,200.85, compared to CNY 15,907,337.94 in the previous year, reflecting a growth of 17.9%[29].

Financial Performance - The company's operating revenue for the first half of 2022 was ¥172,665,706.54, a decrease of 3.11% compared to ¥178,216,549.40 in the same period last year [24]. - The net profit attributable to shareholders increased by 63.94% to ¥43,816,347.55 from ¥26,727,021.75 year-on-year [24]. - The net profit after deducting non-recurring gains and losses was ¥31,920,075.96, reflecting a growth of 31.53% compared to ¥24,269,067.51 in the previous year [24]. - The company's total assets reached ¥1,521,748,407.42, marking an 88.50% increase from ¥807,284,424.94 at the end of the previous year [24]. - The net assets attributable to shareholders rose by 154.15% to ¥1,193,081,006.66 from ¥469,438,292.18 at the end of the previous year [24]. - Basic earnings per share increased by 41.67% to ¥0.85 from ¥0.60 in the same period last year [24]. - The company reported a net cash flow from operating activities of -¥917,506.62, a decline of 102.81% compared to ¥32,669,771.13 in the previous year [24]. - The company's gross profit margin for the first half of 2022 was 31.82%, a decrease from 37.55% in 2021, indicating fluctuations in profitability [116]. Investment and R&D - The company invested CNY 13.86 million in R&D during the reporting period, representing 8.03% of its operating revenue, focusing on high-value products in blood purification and ward care [71]. - The company's R&D investment increased by 36.90% to ¥13,858,657.02 from ¥10,122,845.46, reflecting a commitment to enhancing product development [84]. - The company has a stable R&D team of 110 members, accounting for 9.70% of total employees, with expertise in various fields including polymer materials and biotechnology [70]. - The company holds 37 patents, including 8 invention patents, and has 27 medical device product registration certificates, with 4 additional applications pending [72]. - The company has established partnerships with leading international firms, including Medtronic, to develop blood dialysis system products, demonstrating its recognized R&D capabilities [71]. Market and Product Development - The company specializes in the research, production, and sales of medical polymer consumables for blood purification and ward care, with a strong brand presence and products distributed across 31 provinces in China and exported globally [50]. - The company is focusing on developing new products in the blood purification and ward care fields to meet changing market demands [119]. - The company has a robust pipeline of medical devices, with several products in various stages of registration, showcasing its growth potential in the medical device sector [169]. - The company aims to maintain compliance with regulatory standards by ensuring that all new products undergo thorough registration processes [169]. - The company has introduced new products, including a disposable drainage bag and a laparoscopic fog remover, both classified as Class II devices, with approvals received in 2022 [167]. Compliance and Quality Management - The report emphasizes the importance of accurate financial reporting and the responsibility of management for the report's content [3]. - The report outlines the company's commitment to compliance with regulatory standards, including FDA and CE certifications for its products [15]. - The company has received EN ISO 13485:2016 certification and has been recognized by FDA and EU CE, indicating compliance with international quality standards [75]. - The company maintains a comprehensive quality assurance system, emphasizing the importance of product quality since its establishment in 1998 [73]. - The company has implemented a comprehensive quality management system to ensure product safety and effectiveness, adhering to all relevant regulations throughout the production process [136]. Corporate Governance and Management - All directors attended the board meeting to review the report, ensuring comprehensive oversight [4]. - The financial report includes signatures from key management, ensuring accountability for the accuracy of the financial data presented [9]. - The management team has over 30 years of experience in the medical device industry, contributing to effective strategic planning and market expansion [80]. - The company has maintained a robust internal control system to ensure compliance with relevant laws and regulations, safeguarding shareholder rights [134]. Risks and Challenges - The company is facing risks related to raw material price fluctuations, particularly for key materials like PVC, PP, and ABS, which account for over 40% of total raw material costs [115]. - The concentration of customers poses a risk, as major sales come from specific clients like NeoMed and Nanjing Tianwen, which could impact revenue if lost [120]. - The company has not yet faced significant adverse effects from the centralized procurement policy but acknowledges potential future impacts on pricing and sales volume [121]. Shareholder Information - The company issued 14,736,842 shares of RMB ordinary shares (A shares) on April 7, 2022, following approval from the China Securities Regulatory Commission [174]. - The net profit attributable to the parent company's ordinary shareholders for the first half of 2022 was approximately 43.82 million, compared to 26.73 million in the same period of 2021, representing a year-over-year increase of 64.1% [175]. - The basic earnings per share for the first half of 2022 was 0.85, up from 0.60 in the first half of 2021, indicating a growth of 41.67% [175]. - The total equity attributable to shareholders of the listed company as of June 30, 2022, was approximately 1.19 billion, compared to 469.44 million on June 30, 2021, reflecting a significant increase of 153.5% [175]. - The major shareholder, Wu Zhimin, holds 47.50% of the shares, totaling 28,000,000 shares [182].

Financial Performance - The company's operating revenue for 2021 was ¥414,731,858.47, representing a 9.46% increase compared to ¥378,874,787.39 in 2020 [21]. - The net profit attributable to shareholders for 2021 was ¥78,292,042.29, a decrease of 10.16% from ¥87,149,537.48 in 2020 [21]. - The net profit after deducting non-recurring gains and losses increased by 42.22% to ¥73,074,983.57 from ¥51,382,849.13 in 2020 [21]. - The total assets at the end of 2021 were ¥807,284,424.94, a 19.97% increase from ¥672,903,355.73 at the end of 2020 [21]. - The net assets attributable to shareholders increased by 20.02% to ¥469,438,292.18 from ¥391,146,249.89 in 2020 [21]. - The basic earnings per share for 2021 was ¥1.77, down 10.15% from ¥1.97 in 2020 [21]. - The company reported a net cash flow from operating activities of ¥133,029,877.97, an increase of 9.60% from ¥121,375,903.47 in 2020 [21]. - The company achieved a revenue of CNY 414.73 million in 2021, representing a year-on-year increase of 9.46% [58]. - The net profit attributable to shareholders was CNY 78.29 million, a decrease of 10.16% year-on-year, while the net profit excluding non-recurring gains and losses increased by 42.22% to CNY 73.08 million [58]. - The blood purification product line generated CNY 262.66 million in revenue, accounting for 63.33% of total revenue, with a year-on-year growth of 30.52% [61]. Market Position and Strategy - The company plans to expand its market presence and invest in new product development to enhance growth prospects [21]. - The company ranks second in the domestic extracorporeal circulation bloodline market by sales volume as of 2019, indicating strong competitive positioning [36]. - The company plans to expand into blood purification equipment and is currently developing a continuous renal replacement therapy device, which is in the sample trial phase [35]. - The company aims to enhance its market share in the blood purification consumables sector, positioning itself as a leading comprehensive service provider in medical consumables [101]. - The marketing strategy includes expanding customer resources, particularly targeting Fortune 500 companies, to increase market share both domestically and internationally [102]. - The company plans to enhance its marketing network by deepening cooperation with reputable distributors and direct customers to improve product technology and variety [102]. Research and Development - The company has invested over 20 years in R&D, leading to a robust core technology system that supports product design and production [49]. - The company is advancing several R&D projects aimed at enhancing its blood purification product line, including domestic alternatives to imported products [77]. - In 2021, the company's R&D investment amounted to ¥20,261,432.48, representing 4.89% of total revenue, a year-on-year increase of 26.84% [78]. - The company holds a total of 34 authorized patents and has 10 patents under application as of the end of the reporting period [79]. - The company is currently applying for 6 medical device registration certificates, including a disposable blunt-type arteriovenous fistula puncture needle and a blood dialysis concentrate [79]. - The company has developed new products using new technologies and processes to meet market and user demands, enhancing product value [78]. Corporate Governance and Management - The company has established a sound corporate governance structure, ensuring independence from its controlling shareholders [118]. - The company has not experienced any changes in its board of directors or senior management during the reporting period [125]. - The company’s chairman and general manager, Wu Zhimin, has held his position since May 2016 and has a background in medical device standards [126]. - The company’s vice president, Wu Bin, has been in his role since May 2016 and has experience in sales management [127]. - The board of directors attended all scheduled meetings, with no absences reported [140]. - The audit committee held 3 meetings during the reporting period to review financial reports and internal audit plans [145]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of RMB 2.50 per 10 shares to all shareholders, based on a total of 58,947,368 shares [4]. - The cash dividend distribution plan aligns with the company's articles of association and profit distribution principles [153]. - The cash dividend distribution is part of the company's strategy to reward shareholders while ensuring normal operations and long-term development [153]. - The company has maintained a positive net profit available for distribution to shareholders during the reporting period [154]. Risks and Challenges - The company emphasizes that forward-looking statements regarding operational plans and future strategies do not constitute a commitment or profit forecast to investors [4]. - The company has detailed potential risk factors and countermeasures in the report, urging investors to pay attention to investment risks [4]. - The company faces high customer concentration risk, particularly with key clients like NeoMed and Nanjing Tianwen, which could significantly impact revenue if these clients reduce orders [104]. - The fluctuation of raw material prices, particularly for PVC, PP, and ABS, which accounted for 42.05%, 45.18%, 43.08%, and 45.24% of total raw material costs, poses a risk to production costs [106]. Social Responsibility - The company donated 400,000 RMB to the Ningbo Charity Federation Dongqian Lake Branch during the reporting period [164]. - The company has not engaged in poverty alleviation or rural revitalization efforts during the reporting period [165]. - The company has not faced any administrative penalties related to environmental issues during the reporting period [162].

Financial Performance - The company's operating revenue for Q1 2022 was ¥81,372,982.62, representing a 1.07% increase compared to ¥80,512,287.36 in the same period last year[3] - Net profit attributable to shareholders decreased by 20.19% to ¥9,026,615.21 from ¥11,309,433.07 year-on-year[3] - The net profit after deducting non-recurring gains and losses fell by 31.28% to ¥6,863,477.89, primarily due to increased procurement costs[7] - Basic and diluted earnings per share decreased by 23.08% to ¥0.20, reflecting the decline in net profit[3] - Operating profit decreased to ¥9,858,640.28 from ¥13,048,847.76, a decline of 24.67%[19] - Net profit for Q1 2022 was ¥9,026,732.54, down 20.16% from ¥11,309,433.07 in the same period last year[20] Cash Flow and Expenses - The net cash flow from operating activities dropped by 157.79% to -¥3,677,645.24, attributed to higher procurement expenses and increased R&D investments[7] - Cash flow from operating activities showed a net outflow of ¥3,677,645.24, compared to a net inflow of ¥6,364,105.62 in Q1 2021[22] - The net cash flow from investment activities was negative at ¥-16,142,565.39, down from a positive cash flow of ¥25,246,852.30 in the same period last year[24] - Research and development expenses increased to ¥7,043,416.03 from ¥4,239,384.96, marking a rise of 66.5%[18] Assets and Liabilities - Total assets increased by 89.62% to ¥1,530,805,737.72, mainly due to funds raised from the public issuance of A-shares[7] - The company's total liabilities amounted to CNY 357.18 million, up from CNY 337.85 million, indicating a rise of approximately 5.4%[17] - The company's cash and cash equivalents increased to CNY 1,049.81 million from CNY 345.66 million, representing a growth of about 203.5%[15] - The company reported accounts receivable of CNY 39.23 million, an increase from CNY 32.03 million, representing a growth of approximately 22.6%[15] Shareholder Information - The company reported a total of 18,527 common shareholders at the end of the reporting period[8] - The largest shareholder, Wu Zhimin, holds 47.50% of the shares, totaling 28,000,000 shares[8] - Shareholders' equity attributable to the parent company rose by 149.88% to ¥1,173,028,116.32, also due to the public issuance of A-shares[7] - The company has a total of 44,971,152 restricted shares at the end of the reporting period, with no new restricted shares added during the period[11] Contracts and Future Plans - The company signed a three-year sales contract framework with BIOCARE TECHNOLOGY COMPANY LIMITED for the sale of extracorporeal circulation bloodline products in the Asia-Pacific and Europe regions[12] - The company aims to expand its production capacity and enhance market competitiveness through the successful implementation of its fundraising projects[13] - The future sales volume under the contract with BIOCARE TECHNOLOGY is subject to uncertainty due to market competition and industry policies[12] Stock Market Activity - The company officially listed on the Shenzhen Stock Exchange on April 7, 2022, raising a net amount of CNY 694.56 million, primarily for the construction of production projects and a comprehensive R&D center[13]

Financial Performance - The company's operating revenue for 2021 was ¥414,731,858.47, representing a 9.46% increase compared to ¥378,874,787.39 in 2020[21]. - The net profit attributable to shareholders for 2021 was ¥78,292,042.29, a decrease of 10.16% from ¥87,149,537.48 in 2020[21]. - The net profit after deducting non-recurring gains and losses increased by 42.22% to ¥73,074,983.57 from ¥51,382,849.13 in 2020[21]. - The total assets at the end of 2021 were ¥807,284,424.94, a 19.97% increase from ¥672,903,355.73 at the end of 2020[21]. - The net assets attributable to shareholders increased by 20.02% to ¥469,438,292.18 from ¥391,146,249.89 in 2020[21]. - The basic earnings per share for 2021 was ¥1.77, down 10.15% from ¥1.97 in 2020[21]. - The weighted average return on equity for 2021 was 18.20%, a decrease of 6.87% from 25.07% in 2020[21]. - The net cash flow from operating activities for 2021 was ¥133,029,877.97, an increase of 9.60% from ¥121,375,903.47 in 2020[21]. - The company reported non-recurring gains of ¥5,217,058.72 in 2021, compared to ¥35,766,688.35 in 2020[28]. - The company achieved a revenue of CNY 414.73 million in 2021, representing a year-on-year increase of 9.46%[59]. - The net profit attributable to shareholders was CNY 78.29 million, a decrease of 10.16% year-on-year, while the net profit excluding non-recurring gains and losses increased by 42.22% to CNY 73.08 million[59]. - The company’s total assets grew by 19.97% to CNY 807.28 million, and the net assets attributable to shareholders increased by 20.02% to CNY 469.44 million[59]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of RMB 2.50 per 10 shares to all shareholders, based on a total of 58,947,368 shares[4]. - The company reported a distributable profit of RMB 294,161,703.42 for the year[155]. - The proposed cash dividend totals RMB 14,736,842.00, which represents 18.82% of the distributable profit[155]. - The company did not issue any bonus shares or increase capital from the capital reserve during the reporting period[155]. - The company adheres to a profit distribution policy that ensures clear standards and ratios for dividends, which are reviewed by the board and submitted to the shareholders' meeting[153]. Governance and Compliance - The report emphasizes the importance of accurate financial reporting and the responsibility of management to ensure completeness and truthfulness[3]. - The company has a comprehensive governance structure in place, with all board members present for the report's approval[4]. - The company has established a strategic committee, nomination committee, audit committee, and compensation and assessment committee to ensure effective governance[157]. - The company maintains independence from its controlling shareholders, ensuring that its operations and financials are not influenced by external parties[118]. - The company has a governance structure that includes a board of directors with 7 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[112]. - The company has not engaged in any significant related party transactions that could affect its independence or fairness[123]. - The company has not reported any quality-related medical incidents or disputes with customers during the reporting period, reflecting its commitment to product safety[54]. - The company has established comprehensive internal control systems, including rules for shareholder meetings and board meetings[157]. - The company has adhered to legal and regulatory requirements regarding related party transactions and fund management[158]. Market and Strategic Development - The report includes a detailed discussion on the company's future plans and strategic direction, although these do not constitute binding commitments[4]. - The company is actively involved in research and development of new medical technologies and products to enhance its market position[12]. - The company plans to expand into blood purification equipment and is currently developing a continuous renal replacement therapy device, which is in the sample trial stage[35]. - The company aims to enhance its market share in the blood purification consumables sector, positioning itself as a leading comprehensive service provider in medical consumables[103]. - The company plans to strengthen its R&D system, focusing on a product reserve structure of "developing, registering, and mass-producing" to enhance market competitiveness[103]. - The marketing strategy includes expanding customer resources, particularly targeting Fortune 500 companies, to increase market share both domestically and internationally[104]. - The company has established partnerships with three new distributors in Europe, aiming to enhance distribution channels and increase sales volume[135]. Research and Development - The company has invested over 20 years in R&D, leading to a robust core technology system that supports product design and production[50]. - The total R&D expenses rose to ¥20,261,432.48 in 2021, reflecting a 26.84% increase in external collaboration costs compared to the previous year[77]. - The company holds a total of 34 authorized patents and has 10 patents under application as of the end of the reporting period[80]. - The number of R&D personnel increased to 111 in 2021, up by 1.83% from 109 in 2020, with R&D personnel accounting for 12.56% of the total workforce[79]. - The company is actively developing new products using new technologies and processes to meet market and user demands[79]. Risk Management - The company has outlined potential risks and countermeasures in its future development section, urging investors to be aware of investment risks[4]. - The company faces risks related to high customer concentration, with significant sales of feeding devices and feeding tubes primarily to NeoMed and other major clients, which could impact revenue if these clients reduce orders[106]. - The implementation of centralized procurement policies could significantly affect the company's product prices and sales volumes in key sales regions, potentially leading to decreased gross margins[107]. - The company is exposed to risks from fluctuations in raw material prices, which are influenced by the prices of crude oil and other commodities[108]. Social Responsibility and Community Engagement - The report outlines the company's commitment to social responsibility and environmental considerations in its operations[5]. - The company donated 400,000 RMB to the Ningbo Charity Federation Dongqian Lake Branch during the reporting period[166]. Operational Efficiency - The company has a complete procurement, production, sales, and service system for its medical polymer consumables in the blood purification and ward care fields[42]. - The company employs a "sales-driven production" model, ensuring efficient production based on customer demand and historical sales data[44]. - The company has a high degree of automation in its production lines and a comprehensive quality assurance system[37]. - The company has established a systematic approach to equipment debugging and error correction, fostering a skilled workforce to support its core technology[51]. Employee Management - The company has implemented a competitive salary management system to ensure fair compensation for employees[151]. - The company is focused on creating a harmonious work environment and has established training plans to enhance employee development[152]. - The company employed a total of 888 staff members at the end of the reporting period[149]. - The number of employees receiving salaries during the period was 1,466[149]. - The company has a total of 6 employees with a graduate degree or above, and 57 with a bachelor's degree[150].